PRE-CLINICAL RESEARCH
Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction
Susanne W.M. van den Borne, MD*, ,
Satoshi Isobe, MD, PhD*,
Johan W. Verjans, MD*,
Artiom Petrov, PhD*,
Dagfinn Lovhaug, MSc ,
Peng Li, MD, PhD*,
H. Reinier Zandbergen, MD*,
Youping Ni, MD, PhD*,
Peter Frederik, PhD ,
Jun Zhou, MD*,
Bente Arbo, PhD ,
Astri Rogstad, PhD ,
Alan Cuthbertson, PhD ,
Salah Chettibi, PhD ,
Chris Reutelingsperger, PhD ,
W. Matthijs Blankesteijn, PhD ,
Jos F.M. Smits, PhD ,
Mat J.A.P. Daemen, MD, PhD ,
Faiez Zannad, MD, PhD, FACC ,
Mani A. Vannan, MD, FACC*,
Navneet Narula, MD*,
Bertram Pitt, MD, FACC||,
Leonard Hofstra, MD, PhD and
Jagat Narula, MD, PhD, FACC*,*
* University of California, Irvine School of Medicine, Irvine, California
Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands
GE Healthcare, AS, Oslo, Norway
University Henri Poincaré, Nancy, France
|| University of Michigan, Ann Arbor, Michigan
Manuscript received April 30, 2008;
revised manuscript received July 31, 2008,
accepted July 31, 2008.
* Reprint requests and correspondence: Dr. Jagat Narula, Division of Cardiology, University of California, Irvine School of Medicine, 101 The City Drive, Building 53, Mail Route 81, Orange, California 92868-4080 (Email: narula{at}uci.edu).
Objectives: The purpose of this study was to evaluate interstitial alterations in myocardial remodeling using a radiolabeled Cy5.5-RGD imaging peptide (CRIP) that targets myofibroblasts.
Background: Collagen deposition and interstitial fibrosis contribute to cardiac remodeling and heart failure after myocardial infarction (MI). Evaluation of myofibroblastic proliferation should provide indirect evidence of the extent of fibrosis.
Methods: Of 46 Swiss-Webster mice, MI was induced in 41 by coronary artery occlusion, and 5 were unmanipulated. Of the 41 mice, 6, 6, and 5 received intravenous technitium-99m labeled CRIP for micro–single-photon emission computed tomography imaging 2, 4, and 12 weeks after MI, respectively; 8 received captopril or captopril with losartan up to 4 weeks after MI. Scrambled CRIP was used 4 weeks after MI in 6 mice; the remaining 10 of 46 mice received unradiolabeled CRIP for histologic characterization.
Results: Maximum CRIP uptake was observed in the infarct area; quantitative uptake (percent injected dose/g) was highest at 2 weeks (2.75 ± 0.46%), followed by 4 (2.26 ± 0.09%) and 12 (1.74 ± 0.24%) weeks compared with that in unmanipulated mice (0.59 ± 0.19%). Uptake was higher at 12 weeks in the remote areas. CRIP uptake was histologically traced to myofibroblasts. Captopril alone (1.78 ± 0.31%) and with losartan (1.13 ± 0.28%) significantly reduced tracer uptake; scrambled CRIP uptake in infarct area (0.74 ± 0.17%) was similar to CRIP uptake in normal myocardium.
Conclusions: Radiolabeled CRIP allows for noninvasive visualization of interstitial alterations during cardiac remodeling, and is responsive to antiangiotensin treatment. If proven clinically feasible, such a strategy would help identify post-MI patients likely to develop heart failure.
Key Words: myofibroblasts integrins interstitial fibrosis radionuclide imaging heart failure coronary artery disease
|
Abbreviations and Acronyms
| | ASMA = alpha smooth muscle actin | | CRIP = Cy5.5-RGD imaging peptide | | CT = computed tomography | | HF = heart failure | | LV = left ventricle/ventricular | | MI = myocardial infarction | | PBS = phosphate-buffered saline | | RGD = arginine-glycine-aspartate | | SPECT = single-photon emission computed tomography | | Tc = technetium |
|
Related Articles
-
Fibrosis: A Living Tissue and the Infarcted Heart
- Karl T. Weber, Yao Sun, and Javier Díez
J. Am. Coll. Cardiol. 2008 52: 2029-2031.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A32.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. Saraste, S. G. Nekolla, and M. Schwaiger
Cardiovascular molecular imaging: an overview
Cardiovasc Res,
September 1, 2009;
83(4):
643 - 652.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Whittle
Conflicts of Interest Need to Be Reported Reliably
Arch Intern Med,
June 8, 2009;
169(11):
1078 - 1079.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W.M. van den Borne, S. Isobe, H. R. Zandbergen, P. Li, A. Petrov, N. D. Wong, S. Fujimoto, A. Fujimoto, D. Lovhaug, J. F.M. Smits, et al.
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
187 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Mann
Molecular imaging and the failing heart: through the looking glass.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
199 - 201.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. T. Weber, Y. Sun, and J. Diez
Fibrosis: A Living Tissue and the Infarcted Heart
J. Am. Coll. Cardiol.,
December 9, 2008;
52(24):
2029 - 2031.
[Full Text]
[PDF]
|
 |
|
|